Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Adults

Part of paid clinical trials in Rochester, Minnesota.

Sponsor
Mayo Clinic
Study ID
NCT03675724
Phase
PHASE2
Status
Enrolling By Invitation

Conditions

  • Frail Elderly Syndrome

Eligibility Criteria

Sex
ALL
Age
70 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Fisetin — DIETARY_SUPPLEMENT
    Flavonoid Family
  • Placebo oral capsule — DRUG
    Placebo

Study Details

This is a pilot study to test the efficacy of the anti-inflammatory drug (Fisetin) in reducing inflammatory factors in blood in elderly adults and to test the efficacy of the drug (Fisetin) in reducing frailty and markers of inflammation, insulin resistance, and bone resorption in elderly adults.

Key Dates

Start date
Nov 15, 2018
Status verified
Apr 2026
Primary completion
Nov 30, 2026
Completion
Nov 30, 2027

Study Design

Enrollment
40 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment
    Fisetin 20mg/kg/day, orally for 2 consecutive days
  • Placebo Comparator: Placebo
    Placebo capsules orally for 2 consecutive days

Primary Outcome Measure

Decrease in blood inflammation markers [ Time Frame: Seven Days ]

Locations (1)

FacilityCityStateZIPSite coordinators
Mayo Clinic in RochesterRochesterMinnesota55905-

Find similar trials in Rochester, MN

By research site
Mayo Clinic in Rochester· Rochester, MN

Related Studies